- Home
- EICC vs VCEL Comparison
EICC vs VCEL Comparison
Compare EICC & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EICC
- VCEL
- Stock Information
- Founded
- EICC N/A
- VCEL 1989
- Country
- EICC United States
- VCEL United States
- Employees
- EICC N/A
- VCEL N/A
- Industry
- EICC
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EICC
- VCEL Health Care
- Exchange
- EICC Nasdaq
- VCEL Nasdaq
- Market Cap
- EICC N/A
- VCEL 2.1B
- IPO Year
- EICC N/A
- VCEL 1997
- Fundamental
- Price
- EICC $25.10
- VCEL $40.25
- Analyst Decision
- EICC
- VCEL Strong Buy
- Analyst Count
- EICC 0
- VCEL 8
- Target Price
- EICC N/A
- VCEL $62.00
- AVG Volume (30 Days)
- EICC 18.7K
- VCEL 477.0K
- Earning Date
- EICC 01-01-0001
- VCEL 07-31-2025
- Dividend Yield
- EICC 7.96%
- VCEL N/A
- EPS Growth
- EICC N/A
- VCEL 521.85
- EPS
- EICC 0.55
- VCEL 0.05
- Revenue
- EICC $51,224,692.00
- VCEL $238,541,000.00
- Revenue This Year
- EICC $39.61
- VCEL $23.03
- Revenue Next Year
- EICC $27.28
- VCEL $24.52
- P/E Ratio
- EICC $23.44
- VCEL $780.58
- Revenue Growth
- EICC 68.61
- VCEL 14.80
- 52 Week Low
- EICC $23.75
- VCEL $37.39
- 52 Week High
- EICC $25.25
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- EICC N/A
- VCEL 44.06
- Support Level
- EICC N/A
- VCEL $39.39
- Resistance Level
- EICC N/A
- VCEL $42.61
- Average True Range (ATR)
- EICC 0.00
- VCEL 1.73
- MACD
- EICC 0.00
- VCEL -0.15
- Stochastic Oscillator
- EICC 0.00
- VCEL 24.16
About EICC Eagle Point Income Company Inc. 8.00% Series C Term Preferred Stock due 2029
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.